MedTrace Logo

Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients

NCT00396656 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-06-06

Study results available
· View outcomes & findings →

Summary

This study evaluated the effect of valsartan on small vessel blood flow in patients with mild-to-moderate hypertension in direct comparison to atenolol and hydrochlorothiazide.

Conditions

Interventions

DRUG

Atenolol

100 mg tablets orally once a day (od) in the morning.

DRUG

Hydrochlorothiazide (HCTZ))

12.5 or 25 mg tablets orally once a day (od) in the morning.

DRUG

Valsartan

80 mg, 160 mg, or 320 mg tablets orally once a day in the morning

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharma Ag · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00396656 on ClinicalTrials.gov